Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
BNT162b2
COVID-19
Omicron
SARS-CoV-2
XBB.1.5
booster
vaccine
variant-adapted
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
19
12
2023
revised:
12
01
2024
accepted:
16
01
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of an ongoing, open-label, phase 2/3 study of monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg dose). Healthy participants ≥12 years old (
Identifiants
pubmed: 38400102
pii: vaccines12020118
doi: 10.3390/vaccines12020118
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT05472038', 'NCT05997290']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer Inc
ID : N/A